Genetic Technologies Limited (NASDAQ:GENE) traded up 1% on Tuesday . The company traded as high as $2.28 and last traded at $1.88, 14,388 shares traded hands during trading. A decline of 63% from the average session volume of 39,034 shares. The stock had previously closed at $1.86.
Separately, ValuEngine lowered Genetic Technologies from a “buy” rating to a “hold” rating in a research note on Monday, May 13th.
The company has a fifty day moving average of $0.79 and a 200-day moving average of $0.80.
Genetic Technologies Company Profile (NASDAQ:GENE)
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Featured Article: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.